作者: Manuel Schlageter , Luigi Maria Terracciano , Salvatore D’Angelo , Paolo Sorrentino
DOI: 10.3748/WJG.V20.I43.15955
关键词:
摘要: Hepatocellular carcinoma (HCC) is currently the sixth most common type of cancer with a high mortality rate and an increasing incidence worldwide. Its etiology usually linked to environmental, dietary or life-style factors. HCC commonly arises in cirrhotic liver but interestingly proportion HCCs develop non-fibrotic minimal fibrotic shift underlying can be observed. Although this process yet completely understood, changing scenario also has impact on material seen by pathologists, presenting them new diagnostic dilemmas. Histopathologic criteria for diagnosing classical, progressed are well established known, increase detection small early due routine screening programs, diagnosis these lesions core needle biopsies poses difficult challenge. These far more distinguish from one another than HCC, which clear cut hematoxylin eosin diagnosis. Furthermore thought derive progenitor cells have recently been reclassified WHO. This review summarizes recent developments tries put biomarkers context WHOs reclassification. it addresses group tumors known as combined hepatocellular-cholangiocellular carcinomas.